Therefore, XOR represents a novel therapeutic target for the treatment of MS, and febuxostat, which is already approved for treatment of gout in several countries, may be an important agent to modulate XOR activity and improve outcomes in patients with both RRMS and SPMS. This evidence concerns the gene XDH and gout.